Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOUND-C: Deleobuvir and Faldaprevir +/- Ribavirin in Chronic HCV Genotype 1
NCT01132313Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2010
- Primary completion
- Oct 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of deleobuvir and faldaprevir in hepatitis C (HCV) (12 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Rapid Virological Response at 4 weeks and Sustained Virological Response. Started May 2010; status: completed.
02
Drugs
deleobuvirfaldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01132313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01132313.